{"product_id":"halo-bcg-matrix","title":"(HALO) Halozyme Therapeutics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Halozyme Therapeutics, Inc. BCG Matrix helps you understand how the company’s products or business units are positioned across Stars, Cash Cows, Question Marks, and Dogs, and what that means for strategy and capital allocation. The content shown on this page is a real preview of the actual report, so you can review the format and sample analysis before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eENHANZE platform licensing engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHalozyme Therapeutics, Inc.'s ENHANZE platform is the core growth engine: rHuPH20 helps convert IV biologics to subcutaneous dosing, which can cut infusion time from hours to minutes. It runs through a broad partner base, including Roche, Johnson \u0026amp; Johnson, argenx, and Bristol Myers Squibb, and keeps adding value through new launches and label expansions. In 2025, that model stayed Halozyme Therapeutics, Inc.'s main royalty driver and the key reason the platform fits the Stars quadrant.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDARZALEX FASPRO royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDARZALEX FASPRO is Halozyme Therapeutics, Inc.’s largest royalty engine, with Johnson \u0026amp; Johnson reporting daratumumab sales above $10 billion in 2024. The subcutaneous brand leads SC oncology delivery and targets multiple myeloma and AL amyloidosis, making it a Halozyme cash cow in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePHESGO royalty stream\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePHESGO is a mature Star in Halozyme Therapeutics, Inc.'s BCG view because it combines pertuzumab and trastuzumab with hyaluronidase for HER2-positive breast cancer and keeps expanding subcutaneous use worldwide. Roche reported PHESGO sales of CHF 1.85 billion in 2024, showing strong commercial scale and long life. That broad use supports a durable royalty stream for Halozyme Therapeutics, Inc. and keeps cash flow visible.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVYVGART Hytrulo royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVYVGART Hytrulo royalties are a Star in Halozyme Therapeutics, Inc.’s BCG mix because they turn Argenx’s efgartigimod into a subcutaneous product, which supports faster use and wider access. The franchise now spans gMG and CIDP, two autoimmune neurology markets with clear growth runway. Adoption and geographic reach are still expanding, so royalty upside remains tied to volume growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubcutaneous delivery drives use\u003c\/li\u003e\n\u003cli\u003eTwo growing indications: gMG, CIDP\u003c\/li\u003e\n\u003cli\u003eExpansion is still underway\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOCREVUS ZUNOVO royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOCREVUS ZUNOVO is a Stars asset for Halozyme Therapeutics, Inc. because it brings subcutaneous ocrelizumab into a multiple sclerosis market affecting about 2.9 million people worldwide and about 1 million in the U.S. Its launch adds another high-volume ENHANZE royalty stream, tied to a proven anti-CD20 therapy with broad use. That makes it a key growth driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge, treated MS market\u003c\/li\u003e\n\u003cli\u003eSubcutaneous ocrelizumab launch\u003c\/li\u003e\n\u003cli\u003eHigh-volume ENHANZE royalties\u003c\/li\u003e\n\u003cli\u003eScales with ongoing use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHalozyme’s ENHANZE Stars Keep Delivering Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHalozyme Therapeutics, Inc.’s Stars are the ENHANZE royalty set: DARZALEX FASPRO, PHESGO, VYVGART Hytrulo, and OCREVUS ZUNOVO. In 2024, Johnson \u0026amp; Johnson’s daratumumab sales topped $10 billion and Roche’s PHESGO sales reached CHF 1.85 billion, while VYVGART Hytrulo and OCREVUS ZUNOVO still had clear expansion runway.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eKey 2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDARZALEX FASPRO\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$10B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePHESGO\u003c\/td\u003e\n\u003ctd\u003eCHF 1.85B sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHalozyme’s BCG matrix maps its drug-delivery portfolio into Stars, Cash Cows, Question Marks, and Dogs to guide invest\/hold\/divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page Halozyme Therapeutics BCG Matrix that clarifies each business unit for quick, pain-free strategy reviews\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Halozyme Therapeutics, helping users verify claims quickly and make better-informed decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHylenex recombinant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHylenex recombinant is Halozyme Therapeutics, Inc.'s own recombinant hyaluronidase, used for fluid administration and injection dispersion. It is a mature franchise with stable demand, not a high-growth driver, so it fits the Cash Cows slot in the BCG Matrix. Its long market history and steady use support dependable cash flow rather than rapid expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHYQVIA royalties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHYQVIA royalties fit Halozyme Therapeutics, Inc. as a Cash Cow: the therapy has been on market since 2014 and serves a durable immunodeficiency patient base, so royalty revenue is recurring while marketing spend stays low. In 2025, Halozyme still reported HYQVIA as an established royalty stream, supporting cash flow without heavy launch costs. That makes it a mature, low-growth but reliable contributor.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy mature licensing fees\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHalozyme Therapeutics, Inc. gets steady cash from legacy ENHANZE licensing fees tied to older partner deals, and those contracts need little added commercial support. That makes this a classic Cash Cow: low reinvestment, predictable royalties, and high margin cash flow. In 2025, Halozyme kept using this base to fund growth in newer programs while preserving earnings quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEstablished global immunology installs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHalozyme Therapeutics, Inc.'s global immunology installs are a cash cow because its ENHANZE-enabled subcutaneous products sit in chronic care paths, so patients keep using them and royalties recur. The base is broad, with more than 10 commercial partnered products and 500,000+ cumulative infusions in prior disclosures, which helps support steady cash flow even in a low-growth segment.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring use in chronic therapy\u003c\/li\u003e\n\u003cli\u003eEmbedded in global immunology care\u003c\/li\u003e\n\u003cli\u003eStable royalty-driven cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLong-tail royalty income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHalozyme Therapeutics, Inc.'s long-tail royalty income still matters because older ENHANZE deals keep paying royalties and milestones, while revenue is spread across multiple licensees instead of one drug. That mix helps smooth cash generation across cycles, and by 2025 the company still had a broad partnered base supporting recurring royalty cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOlder assets still pay royalties.\u003c\/li\u003e\n\u003cli\u003eMultiple licensees reduce concentration.\u003c\/li\u003e\n\u003cli\u003eCash flow stays steadier across cycles.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHalozyme’s Cash Cows Keep 2025 Cash Flow Steady\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHalozyme Therapeutics, Inc.'s Cash Cows are Hylenex recombinant and legacy ENHANZE royalties: mature, low-growth, and still cash-generative in 2025.\u003c\/p\u003e\n\u003cp\u003eHYQVIA royalties also stayed recurring, with a durable immunodeficiency base and low added sales spend.\u003c\/p\u003e\n\u003cp\u003eHalozyme Therapeutics, Inc. had more than 10 commercial partnered products and 500,000+ cumulative infusions, which helped keep cash flow steady.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHylenex recombinant\u003c\/td\u003e\n\u003ctd\u003eMature, stable demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHYQVIA royalties\u003c\/td\u003e\n\u003ctd\u003eRecurring 2025 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eHalozyme Therapeutics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis Halozyme Therapeutics, Inc. BCG Matrix preview is the exact same document you’ll receive after purchase. No demo pages, no hidden changes—just the full, professionally formatted report. Download it instantly and use it for analysis, presentations, or strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRITUXAN HYCELA\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRITUXAN HYCELA is a legacy oncology asset for Halozyme, built on rituximab and used in subcutaneous delivery. The product faces biosimilar pressure in rituximab, and the market has shown slower growth, so it is no longer a flagship driver for Halozyme. In Halozyme's 2025 mix, growth is led by newer partnered assets, not RITUXAN HYCELA.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMABTHERA SC\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMABTHERA SC is a Dog in Halozyme Therapeutics, Inc.’s BCG view: it is the ex-U.S. rituximab SC franchise in a mature anti-CD20 market, so growth is limited and pricing power is weak. Compared with newer ENHANZE launches, its revenue mix is small and expansion is slower, which fits a low-growth, low-share profile. It adds cash flow, but it is not a major growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRITUXAN SC legacy use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRITUXAN SC is a legacy asset in a crowded rituximab market that has faced biosimilar pressure since 2017. Demand is softer as switch dynamics and lower-priced rivals cap growth, while Roche reported RITUXAN sales of about $1.1 billion in 2024, down sharply from peak years. That makes it a low-growth, low-share Dogs name in Halozyme Therapeutics, Inc.’s BCG matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall-volume mature oncology conversions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOlder SC conversion products in hematology are the Dogs in Halozyme Therapeutics, Inc.’s BCG view: they still throw off residual cash, but momentum is far weaker than newer franchises and their market role is well below the company’s top assets. In 2025, Halozyme still leaned on ENHANZE royalty streams, but these legacy products look like low-growth holdovers, not growth engines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eResidual cash flow, not growth\u003c\/li\u003e\n\u003cli\u003eWeaker than newer franchises\u003c\/li\u003e\n\u003cli\u003eBelow top-asset market position\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInactive or dormant partner programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHalozyme Therapeutics, Inc.’s inactive partner programs are legacy collaborations that no longer drive meaningful commercial revenue. They use little capital and require limited ongoing attention, but they also add almost no growth, so they sit in the BCG “dog” bucket. The value today comes from core ENHANZE partners, while these dormant deals mostly sit on the sidelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow capital use, low revenue\u003c\/li\u003e\n\u003cli\u003eNo clear growth contribution\u003c\/li\u003e\n\u003cli\u003eLegacy value only, not a driver\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHalozyme’s Dogs: Legacy Deals Under Pressure, ENHANZE Takes Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHalozyme Therapeutics, Inc.’s Dogs are legacy SC rituximab products and inactive partner deals that add cash but little growth. In 2025, the franchise stayed under pressure from biosimilars and slow anti-CD20 demand, so it fits a low-share, low-growth BCG slot. The focus is on ENHANZE royalties, not these holdovers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDogs item\u003c\/th\u003e\n\u003cth\u003e2025 view\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRITUXAN HYCELA\u003c\/td\u003e\n\u003ctd\u003eLegacy, pressured\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMABTHERA SC\u003c\/td\u003e\n\u003ctd\u003eSmall, mature\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInactive partners\u003c\/td\u003e\n\u003ctd\u003eMinimal revenue\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTecentriq SC program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTecentriq SC is a question mark: it targets a huge oncology pool, but it must win share from entrenched IV atezolizumab and rival PD-1\/PD-L1 drugs. Roche reported Tecentriq sales of about CHF 3.9 billion in 2024, so the SC form could matter if it lifts convenience and site-of-care savings. For Halozyme, that is high upside, low current share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNivolumab SC program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNivolumab SC sits in a blockbuster market: Opdivo has been a $9B+ annual franchise, so even modest conversion from IV could be meaningful for Halozyme Therapeutics, Inc. The key risk is uptake, because oncologists must switch from a proven IV routine to a newer SC option. Early share, not demand, is the main unknown.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eARGX-113 SC expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eARGX-113, the efgartigimod SC franchise, is a clear Question Mark because new autoimmune labels can widen the market fast, but share is still early. Vyvgart Hytrulo already moved beyond generalized myasthenia gravis, and the CIDP approval gave it a second large indication. Halozyme’s ENHANZE base has shown SC delivery can scale, but this asset still needs more real-world uptake to prove its profit pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eARGX-117 pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eARGX-117 is a Question Mark in Halozyme Therapeutics, Inc.’s BCG view: it targets autoimmune disease, but it is still in development and has no sales base or proven share yet. That means the asset has upside if trials and launch go well, but it also carries high clinical and commercial risk. In BCG terms, it needs capital before it can become a cash generator.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAutoimmune pipeline asset\u003c\/li\u003e\n\u003cli\u003ePre-revenue, no market share\u003c\/li\u003e\n\u003cli\u003eHigh upside, high risk\u003c\/li\u003e\n\u003cli\u003eNeeds funding to scale\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBMS-986179 collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBMS-986179 is an early-stage anti-CD73 antibody partnership for Halozyme Therapeutics, Inc., so it fits a question mark: high market upside, but no proven share yet. Oncology immunotherapy is still a huge field, with global cancer spending and checkpoint-style programs driving deal flow, but CD73 assets face high clinical and competitive risk before any clear payoff.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartnered, early-stage asset\u003c\/li\u003e\n\u003cli\u003eLarge oncology immunotherapy market\u003c\/li\u003e\n\u003cli\u003eShare is not yet established\u003c\/li\u003e\n\u003cli\u003eHigh development risk remains\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHalozyme’s Q Marks: Big Upside, Little Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHalozyme Therapeutics, Inc.’s question marks are early bets with large upside but little proven share yet. Tecentriq SC and Nivolumab SC sit in multibillion-franc and $9B+ oncology markets, while ARGX-117 and BMS-986179 are still pre-revenue. They need adoption or trial wins to move toward stars.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eWhy Q mark\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTecentriq SC\u003c\/td\u003e\n\u003ctd\u003eCHF 3.9B 2024 base\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNivolumab SC\u003c\/td\u003e\n\u003ctd\u003e$9B+ franchise\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eARGX-117\u003c\/td\u003e\n\u003ctd\u003ePre-revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBMS-986179\u003c\/td\u003e\n\u003ctd\u003eEarly-stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234472108297,"sku":"halo-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/halo-bcg-matrix.webp?v=1785720617","url":"https:\/\/dcfanalyst.com\/products\/halo-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}